T14 Intrinsic Stock Value – TIANJIN PHARMACEUTICAL DA REN TANG Reports Q2 FY2023 Earnings, Ending June 30 2023

August 26, 2023

🌥️Earnings Overview

On August 15th 2023, TIANJIN PHARMACEUTICAL DA REN TANG ($SGX:T14) released its financial results for the second quarter of FY2023, which ended on June 30th 2023. Total revenue for the quarter was reported as CNY 1933.9 million, an increase of 2.6% compared to the same quarter in the previous year. Net income increased 19.5% year-over-year to CNY 321.7 million.

Stock Price

TIANJIN PHARMACEUTICAL DA REN TANG reported its earnings for the second quarter of FY2023 on Tuesday, revealing a slight decrease in its stock value. The company opened its shares at SG$1.9 and closed the day at SG$1.9, representing a 2.5% decrease from the closing price of SG$2.0 on its previous trading day. Despite this drop, the company has maintained an encouraging outlook for the rest of its fiscal year, as it expects to be able to bounce back and increase stock value in the upcoming quarters. The company has plans to explore new business opportunities and bolster international relations to expand its reach, and believes that these strategies will help drive higher stock prices in the future. It is also making plans to diversify its portfolio by introducing new products and services, which has already led to positive feedback from investors.

Overall, TIANJIN PHARMACEUTICAL DA REN TANG remains confident in its ability to deliver positive results in the upcoming quarters, and is ready to take on the challenges of the ever-changing global market. The company’s commitment to offering innovative solutions and expanding its presence worldwide are sure to be beneficial in achieving its goals. With this in mind, it is expected that TIANJIN PHARMACEUTICAL DA REN TANG will soon be back on track as it continues to strive for success. Live Quote…

About the Company

  • Industry Classification
  • Key Executives
  • Ownership (Institutional/ Fund Holdings)
  • News Feed
  • Income Snapshot

    Below shows the total revenue, net income and net margin for T14. More…

    Total Revenues Net Income Net Margin
    8.56k 1.12k 13.6%
  • Income Statement Reports (Yearly/ Quarterly/ LTM)
  • Income Supplement
  • Growth Performance
  • Cash Flow Snapshot

    Below shows the cash from operations, investing and financing for T14. More…

    Operations Investing Financing
    710.62 -1.02k -199.52
  • Cash Flow Statement (Yearly/ Quarterly/ LTM)
  • Cash Flow Supplement
  • Balance Sheet Snapshot

    Below shows the total assets, liabilities and book value per share for T14. More…

    Total Assets Total Liabilities Book Value Per Share
    10.36k 3.97k 8.22
  • Balance Sheet (Yearly/ Quarterly)
  • Balance Sheet Supplement
  • Key Ratios Snapshot

    Some of the financial key ratios for T14 are shown below. More…

    3Y Rev Growth 3Y Operating Profit Growth Operating Margin
    8.2% 15.5% 14.8%
    FCF Margin ROE ROA
    6.9% 11.9% 7.6%
  • Income Statement Ratios
  • Balance Sheet Ratios
  • Cash Flow Ratios
  • Valuation Ratios
  • Other Ratios
  • Other Supplementary Items
  • Analysis – T14 Intrinsic Stock Value

    At GoodWhale, we have conducted an analysis of the wellbeing of TIANJIN PHARMACEUTICAL DA REN TANG. Our proprietary Valuation Line has calculated the fair value of their share to be around SG$1.2. However, the stock of TIANJIN PHARMACEUTICAL DA REN TANG is currently being traded at SG$1.9, which is overvalued by 53.5%. This implies that the market sentiment is overvaluing TIANJIN PHARMACEUTICAL DA REN TANG’s shares. Investors should take this into consideration before making any investment decisions on the company’s stock. More…

  • Risk Rating Analysis
  • Star Chart Analysis
  • Valuation Analysis

  • Summary

    Tianjin Pharmaceutical Da Ren Tang has delivered another strong quarter, with total revenue increasing 2.6% year-over-year and net income increasing 19.5% year-over-year. The company has been able to capitalize on growth opportunities and deliver impressive returns for investors. Going forward, analysts believe that the company will continue to benefit from its strong performance and deliver solid returns for shareholders. With a strong brand, experienced management, and sound business strategy, Tianjin Pharmaceutical Da Ren Tang appears to be well-positioned for long-term success.

    Recent Posts

    Leave a Comment